The authors examined whether DDAH1 has any physiological role in prostate cancer (PCa) progression. Using overexpression of DDAH1 in PCa cell lines, they found that DDAH1 promotes cell proliferation, migration and invasion by lowering ADMA levels, as well as increasing nitric oxide production. [Angiogenesis]
Abstract

The authors found no associations between smoking status and telomere length or variability in stromal cells or cancer cells. However, among men without comorbidities, current smokers and former smokers who quit <10 years ago had the most variable telomere length in stromal cells and in cancer cells. [Prostate]
Abstract

The authors focus on the role of glucose transporters (GLUTs) along with prostate cancer progression, and the involvement of GLUT4 on castration-resistant phenotype transition would be considered. [Int J Cancer]
Abstract

Visit our
reviews
page to see a complete list of reviews in
the prostate cell research field.

Janssen-Cilag International NV announced that the European Commission has granted approval to broaden the existing marketing authorization for ZYTIGA® plus prednisone/prednisolone to include an earlier stage of metastatic prostate cancer than its current indications. [Janssen-Cilag International NV]
Press Release

The Leukemia & Lymphoma Society® (LLS) committed an additional $46 million to fund the most innovative science at leading medical institutions around the world, including Memorial Sloan Kettering Cancer Center in New York, Dana-Farber Cancer Institute in Boston, City of Hope in Duarte, California, and the Walter & Eliza Hall Institute of Medical Research in Australia. [The Leukemia & Lymphoma Society®]
Press Release

Some 75 Nobel prizewinners have called on the Iranian government to release Ahmadreza Djalali, a researcher in disaster medicine who was sentenced to death last month. The letter is the latest and most powerful protest against the ruling by the scientific community so far. [Nature News]
Editorial

Ten months into his presidency, Donald Trump has yet to name a science advisor. It’s the longest amount of time a modern president has taken to nominate someone to the position since at least 1976, when Congress established the White House’s Office of Science and Technology Policy. [MIT Technology Review]
Editorial

The controversial director of the office that polices research fraud in U.S.-funded biomedical labs is temporarily moving to another agency. Kathy Partin has been removed after nearly two years as director of the U.S. Office of Research Integrity in Rockville, Maryland, according to Retraction Watch. [ScienceInsider]
Editorial

The European Medicines Agency, charged with evaluating human and animal medicinal products for the European Union, will relocate to Amsterdam after it was selected in a draw of lots between it and Milan. [ScienceInsider]
Editorial